{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T20:54:06Z","timestamp":1763499246586},"reference-count":33,"publisher":"Japanese Society of Internal Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2015]]},"DOI":"10.2169\/internalmedicine.54.3397","type":"journal-article","created":{"date-parts":[[2015,2,28]],"date-time":"2015-02-28T17:21:54Z","timestamp":1425144114000},"page":"525-529","source":"Crossref","is-referenced-by-count":12,"title":["Myopathy and Eosinophilic Pneumonia Coincidentally Induced by Treatment with Daptomycin"],"prefix":"10.2169","volume":"54","author":[{"given":"Hideharu","family":"Hagiya","sequence":"first","affiliation":[{"name":"Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kou","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kikuko","family":"Asano","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Terasaka","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Nada","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eri","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Waseda","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Hanayama","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumio","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 38: 994-1000, 2004.","DOI":"10.1086\/383472"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant <i>Staphylococcus aureus<\/i> infections in adults and children. Clin Infect Dis 52: e18-e55, 2011.","DOI":"10.1093\/cid\/ciq146"},{"key":"3","unstructured":"3. Package insert. Cubicin (Daptomycin) Injection, Cubist Pharmaceuticals, Lexington, MA: November 2010."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 38: 1673-1681, 2004.","DOI":"10.1086\/420818"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Fowler VG Jr., Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by <i>Staphylococcus aureus<\/i>. N Engl J Med 355: 653-665, 2006.","DOI":"10.1056\/NEJMoa053783"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Papadopoulos S, Ball AM, Liewer SE, et al. Rhabdomyolysis during therapy with daptomycin. Clin Infect Dis 42: e108-e110, 2006.","DOI":"10.1086\/504379"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Gonzalez-Ruiz A, Beiras-Fernandez A, Lehmkuhl H, et al. Clinical experience with daptomycin in Europe: the first 2.5 years. J Antimicrob Chemother 66: 912-919, 2011.","DOI":"10.1093\/jac\/dkq528"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hayes D Jr., Anstead MI, Kuhn RJ. Eosinophilic pneumonia induced by daptomycin. J Infect 54: e211-e213, 2007.","DOI":"10.1016\/j.jinf.2006.11.006"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Raad I, Hanna H, Jiang Y, et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 51: 1656-1660, 2007.","DOI":"10.1128\/AAC.00350-06"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kushlaf HA. Emerging toxic neuropathies and myopathies. Neurol Clin 29: 679-687, 2011.","DOI":"10.1016\/j.ncl.2011.05.009"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Bhavnani SM, Rubino CM, Ambrose PG, et al. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 50: 1568-1574, 2010.","DOI":"10.1086\/652767"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Oleson FB Jr., Berman CL, Kirkpatrick JB, et al. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 44: 2948-2953, 2000.","DOI":"10.1128\/AAC.44.11.2948-2953.2000"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Echevarria K, Datta P, Cadena J, et al. Severe myopathy and possible hepatotoxicity related to daptomycin. J Antimicrob Chemother 55: 599-600, 2005.","DOI":"10.1093\/jac\/dki058"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Edwards CM, King K, Garcia RJ. Early-onset rhabdomyolysis associated with daptomycin. Infect Dis Clin Pract 14: 327-328, 2006.","DOI":"10.1097\/01.idc.0000219054.28051.b4"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Colomba C, Rubino R, Siracusa L, et al. Rhabdomyolysis associated with the co-administration of daptomycin and pegylated interferon alpha-2b and ribavirin in a patient with hepatitis C. J Antimicrob Chemother 67: 249-250, 2012.","DOI":"10.1093\/jac\/dkr398"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Patel SJ, Samo TC, Suki WN. Early-onset rhabdomyolysis related to daptomycin use. Int J Antimicrob Agents 30: 472-474, 2007.","DOI":"10.1016\/j.ijantimicag.2007.07.009"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Cobb E, Kimbrough RC, Nugent KM, et al. Organizing pneumonia and pulmonary eosinophilic infiltration associated with daptomycin. Ann Pharmacother 41: 696-701, 2007.","DOI":"10.1345\/aph.1H372"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kakish E, Wiesner AM, Winstead PS, Bensadoun ES. Acute respiratory failure due to daptomycin induced eosinophilic pneumonia. Respiratory Medicine CME 1: 235-237, 2008.","DOI":"10.1016\/j.rmedc.2008.07.010"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Shinde A, Seifi A, DelRe S, et al. Daptomycin-induced pulmonary infiltrates with eosinophilia. J Infect 58: 173-174, 2009.","DOI":"10.1016\/j.jinf.2008.11.001"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Miller BA, Gray A, Leblanc TW, et al. Acute eosinophilic pneumonia secondary to daptomycin: a report of three cases. Clin Infect Dis 50: e63-e68, 2010.","DOI":"10.1086\/652656"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Lal Y, Assimacopoulos AP. Two cases of daptomycin-induced eosinophilic pneumonia and chronic pneumonitis. Clin Infect Dis 50: 737-740, 2010.","DOI":"10.1086\/650487"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kalogeropoulos AS, Tsiodras S, Loverdos D, et al. Eosinophilic pneumonia associated with daptomycin: a case report and a review of the literature. J Med Case Rep 5: 13, 2011.","DOI":"10.1186\/1752-1947-5-13"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Kim PW, Sorbello AF, Wassel RT, et al. Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports. Drug Saf 35: 447-457, 2012.","DOI":"10.2165\/11597460-000000000-00000"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Rether C, Conen A, Grossenbacher M, et al. A rare cause of pulmonary infiltrates one should be aware of: a case of daptomycin-induced acute eosinophilic pneumonia. Infection 39: 583-585, 2011.","DOI":"10.1007\/s15010-011-0148-y"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Phillips J, Cardile AP, Patterson TF, et al. Daptomycin-induced acute eosinophilic pneumonia: analysis of the current data and illustrative case reports. Scand J Infect Dis 45: 804-808, 2013.","DOI":"10.3109\/00365548.2013.805427"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Rajagopal A, Mintz E, Reese L. Daptomycin-induced eosinophilic pneumonia without peripheral eosinophilia. Chest 145: 127A, 2014.","DOI":"10.1378\/chest.1775453"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Allen JN. Drug-induced eosinophilic lung disease. Clin Chest Med 25: 77-88, 2004.","DOI":"10.1016\/S0272-5231(03)00141-2"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 191: 2149-2152, 2005.","DOI":"10.1086\/430352"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Kullar R, Davis SL, Levine DP, et al. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy 31: 527-536, 2011.","DOI":"10.1592\/phco.31.6.527"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Moise PA, Hershberger E, Amodio-Groton MI, et al. Safety and clinical outcomes when utilizing high-dose (&gt; or =8 mg\/kg) daptomycin therapy. Ann Pharmacother 43: 1211-1219, 2009.","DOI":"10.1345\/aph.1M085"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Falcone M, Russo A, Venditti M, et al. Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant <i>Staphylococcus aureus<\/i> bacteremia. Clin Infect Dis 57: 1568-1576, 2013.","DOI":"10.1093\/cid\/cit582"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Lai CC, Sheng WH, Wang JT, et al. Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patients. BMC Infect Dis 13: 66, 2013.","DOI":"10.1186\/1471-2334-13-66"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Odero RO, Cleveland KO, Gelfand MS. Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase inhibitor. J Antimicrob Chemother 63: 1299-1300, 2009.","DOI":"10.1093\/jac\/dkp127"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T02:29:44Z","timestamp":1498184984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/54\/5\/54_54.3397\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.54.3397","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}